| Jane L Emerick, MD | |
|
625 Africa Rd Ste 320, Westerville, OH 43082 | |
| (614) 508-0110 | |
| Not Available |
| Full Name | Jane L Emerick |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 40 Years |
| Location | 625 Africa Rd Ste 320, Westerville, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053307066 | NPI | - | NPPES |
| 0746723 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 35-054130 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Carmel East & West | Columbus, OH | Hospital |
| Mount Carmel St Ann's | Westerville, OH | Hospital |
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Ohio Primary Care Physicians, Inc. | 2769383785 | 488 |
News Archive
BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.
The American Physical Therapy Association is pointing to a new study on low back pain in Medicare patients in its efforts to encourage the newly established Center for Medicare and Medicaid Innovation to promptly launch a demonstration project on direct access to physical therapist services that was recommended in the recent health reform law.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath's request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.
› Verified 6 days ago
| Entity Name | Central Ohio Primary Care Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194705194 PECOS PAC ID: 2769383785 Enrollment ID: O20040114000204 |
News Archive
BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.
The American Physical Therapy Association is pointing to a new study on low back pain in Medicare patients in its efforts to encourage the newly established Center for Medicare and Medicaid Innovation to promptly launch a demonstration project on direct access to physical therapist services that was recommended in the recent health reform law.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath's request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jane L Emerick, MD 625 Africa Rd Ste 320, Westerville, OH 43082-9808 Ph: (614) 508-0110 | Jane L Emerick, MD 625 Africa Rd Ste 320, Westerville, OH 43082 Ph: (614) 508-0110 |
News Archive
BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.
The American Physical Therapy Association is pointing to a new study on low back pain in Medicare patients in its efforts to encourage the newly established Center for Medicare and Medicaid Innovation to promptly launch a demonstration project on direct access to physical therapist services that was recommended in the recent health reform law.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath's request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.
› Verified 6 days ago
Leah Wangeci Muthuri, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 625 Africa Rd Ste 240, Westerville, OH 43082 Phone: 614-508-2672 Fax: 614-508-2668 | |
Dr. John Joseph Ward, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 430 Altair Pkwy Ste 110, Westerville, OH 43082 Phone: 614-754-5500 Fax: 614-754-5501 | |
Nami L Cho, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 555 W Schrock Rd, Suite 110, Westerville, OH 43081 Phone: 614-882-0708 Fax: 614-882-2878 | |
Scott W Johnson, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 655 Africa Rd, Westerville, OH 43082 Phone: 614-326-2672 | |
Dr. David Brian Mcclure, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Polaris Pkwy, Ste 3400, Westerville, OH 43082 Phone: 614-533-3475 Fax: 614-533-3480 | |
John B Krupko, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 625 Africa Rd Ste 200, Westerville, OH 43082 Phone: 614-891-8080 Fax: 614-891-7078 | |
Michael J Dial, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 6100 N Hamilton Rd, Westerville, OH 43081 Phone: 614-814-8490 Fax: 614-814-8520 |